How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor?

How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor?

How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Keith A.A. Fox, MBChB, FRCP, FMedSci

Keith A.A. Fox, MBChB, FRCP, FMedSci

Professor, University of Edinburgh Department of Cardiovascular Medicine Professor, University and Royal Infirmary Edinburgh, United Kingdom